Homology Medicines Inc. CEO Arthur Tzianabos told BioWorld that the new $83.5 million in series B money should let the firm "move our lead program all the way through a phase I/II proof-of-concept trial" while edging toward the clinic with the AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) platform at the same time.